• 1
    Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 709.
  • 2
    Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
  • 3
    IARC. Agents classified by the IARC monographs, vols. 1–100. Lyon, France.
  • 4
    Calleja-Macias IE, Kalantari M, Allan B, et al. Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J Virol 2005; 79: 65659.
  • 5
    Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 267586.
  • 6
    Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10: Lyon, France: International Agency for Research on Cancer, 2010.
  • 7
    Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 149.
  • 8
    de Roda Husman AM, Walboomers JM, van den Brule AJ, et al. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 105762.
  • 9
    Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 250817.
  • 10
    Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 35761.
  • 11
    Schmitt M, Dondog B, Waterboer T, et al. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008; 46: 10509.
  • 12
    Schmitt M, Bravo IG, Snijders PJ, et al. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44: 50412.
  • 13
    Arbyn M, Van Oyen H. Cervical cancer screening in Belgium. Eur J Cancer 2000; 36: 21917.
  • 14
    Vassilakos P, Griffin S, Megevand E, et al. CytoRich liquid-based cervical cytologic test. Screening results in a routine cytopathology service. Acta Cytol 1998; 42: 198202.
  • 15
    Benoy IH, Vanden Broeck D, Ruymbeke MJ, et al. Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol 2011; 205: 569 e1–7.
  • 16
    Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. J Am Med Assoc 2002; 287: 21149.
  • 17
    Depuydt CE, Vereecken AJ, Salembier GM, et al. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer 2003; 88: 5606.
  • 18
    Depuydt CE, Benoy IH, Bailleul EJ, et al. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 2006; 17: 37481.
  • 19
    Snijders PJ, van den Brule AJ, Jacobs MV, et al. HPV DNA detection and typing in cervical scrapes. Methods Mol Med 2005; 119: 10114.
  • 20
    Schmitt M, Dondog B, Waterboer T, et al. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 2010; 48: 1439.
  • 21
    Brummer O, Hollwitz B, Bohmer G, et al. Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia. Gynecol Oncol 2006; 102: 51722.
  • 22
    van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 77987.
  • 23
    Sabol I, Salakova M, Smahelova J, et al. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol 2008; 46: 160613.
  • 24
    Arbyn M, Benoy I, Simoens C, et al. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 2009; 18: 32130.
  • 25
    Baay MF, Tjalma WA, Weyler J, et al. Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer. Eur J Gynaecol Oncol 2001; 22: 2048.
  • 26
    Baay MF, Tjalma WA, Lambrechts HA, et al. Combined Pap and HPV testing in primary screening for cervical abnormalities: should HPV detection be delayed until age 35? Eur J Cancer 2005; 41: 27048.
  • 27
    Schmitt M, Dondog B, Waterboer T, et al. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 2010; 48: 1439.
  • 28
    Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol 2006; 103: 127.
  • 29
    Iftner T, Villa LL. Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr 2003; 31: 808.
  • 30
    de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 104856.